Oral albuterol dosing during the latter stages of a resistance exercise program

J Strength Cond Res. 2005 Feb;19(1):102-7. doi: 10.1519/R-14793.1.


Subjects performed isoload variable resistance exercise (REX) 3 days per week. After 10 weeks, they received a double-blind albuterol (n = 11) or placebo (n = 11) capsule assignment with no crossover and continued training. During the first week of capsule administration, dosages were increased from 4 mg to 16 mg daily and then maintained for 14 days. At weeks 0, 10, and 13, we measured upper arm and thigh cross-sectional area, knee and elbow extensor and flexor (KE, KF, EE, EF) strength at 3 angular velocities, and lean body mass. Data after 10 weeks showed insignificant between-group differences. From weeks 10-13, as subjects continued REX training, albuterol evoked higher (p < 0.05) KE-KF strength gains at multiple velocities versus placebo dosing. A higher lean body mass trend also occurred with albuterol from weeks 10-13. Results suggest that albuterol augments REX to provide greater strength gains from hypertrophic factors than an REX-placebo assignment.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adrenergic beta-Agonists / pharmacology*
  • Adult
  • Albuterol / pharmacology*
  • Body Composition / drug effects
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Humans
  • Male
  • Muscle, Skeletal / drug effects*
  • Physical Education and Training*
  • Weight Lifting / physiology*


  • Adrenergic beta-Agonists
  • Albuterol